RAPT Therapeutics Receives HSR Clearance for GSK Acquisition, Addresses Shareholder Lawsuits

summarizeSummary

RAPT Therapeutics filed an amendment to its Schedule 14D-9, announcing the satisfaction of a key regulatory condition for its acquisition by GSK and disclosing new shareholder lawsuits challenging prior disclosures.

check_boxKey Events

• HSR Act Waiting Period Expired

  The waiting period under the HSR Act expired on February 23, 2026, satisfying a key regulatory condition for the tender offer by GSK to acquire RAPT Therapeutics. This significantly de-risks the acquisition's completion.

• Shareholder Lawsuits and Demand Letters Disclosed

  The company disclosed two new shareholder complaints filed in New York and twelve demand letters from purported stockholders, challenging certain disclosures in the original Schedule 14D-9 related to the acquisition. The company denies the allegations but is voluntarily supplementing disclosures to avoid delay.

• Supplemental Financial Opinion Details

  The filing includes additional details and amendments to J.P. Morgan's fairness opinion, including specifics on the discounted cash flow analysis, premia analysis, and analyst price targets, as well as J.P. Morgan's compensation and relationships with GSK.

auto_awesomeAnalysis

This amendment provides a critical update on the pending acquisition by GSK, confirming the expiration of the HSR Act waiting period. This removes a significant regulatory hurdle, increasing the certainty of the deal's completion. The disclosure of new shareholder lawsuits and demand letters introduces a potential, albeit denied by the company, risk of delay or increased costs, which investors should monitor. The supplemental details regarding J.P. Morgan's fairness opinion offer additional transparency on the valuation process.